

## **Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils**

Samuel Bismut<sup>1,4</sup>, Matthias M. Schneider<sup>2,4</sup>, Masashi Miyasaki<sup>1</sup>, Yuqing Feng<sup>3</sup>, Ellis J. Wilde<sup>1</sup>, M. Dylan Gunawardena<sup>1</sup>, Tuomas P.J. Knowles<sup>2</sup>, Gabrielle S. Kaminski Schierle<sup>3</sup>, Laura S. Itzhaki<sup>1</sup> and Janet R. Kumita<sup>1,\*</sup>

<sup>1</sup>Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, UK, CB2 1PD

<sup>2</sup>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK, CB2 1EW

<sup>3</sup>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK, CB3 0AS

<sup>4</sup>These authors contributed equally

\*Correspondence: Janet Kumita, Department of Pharmacology, University of Cambridge, Cambridge UK, CB2 1PD. E-mail: [jrk38@cam.ac.uk](mailto:jrk38@cam.ac.uk)

**Running title:** Selective binders of alpha-synuclein fibrils

**Manuscript pages:** 16

**Supplementary Information pages:** 6

**Tables:** 2

**Figures:** 4

**Supplementary Information:** The file “Bismut Schneider et al SI 2025.pdf”, contains a table of the amino acid sequences for all designed protein scaffolds, characterization of control protein scaffolds and additional experiments to support the main manuscript.

**Abstract:**

Amyloid fibrils are ordered aggregates that are a pathological hallmark of many neurodegenerative disorders including Alzheimer's Disease and Parkinson's Disease. The process of amyloid formation involves a complex cascade by which soluble monomeric protein converts to insoluble, ordered aggregates (amyloid fibrils). Although inhibiting the aggregation pathway is a key target for therapeutic development, the heterogeneous collection of aggregation-prone species formed in this process, including oligomers, protofibrils and fibrils, represent other targets for modifying disease pathology. Developing molecules that can bind to amyloid fibrils and potentially disrupt the harmful interactions between the fibrils and the cellular components would be advantageous. Designing peptide modulators for  $\alpha$ -synuclein aggregation is of great interest, however effective inhibitory peptides are often hydrophobic and hence difficult to handle; therefore, developing strategies to display these peptides in a soluble scaffold would be very beneficial. Here we demonstrate that the ultra-stable consensus-designed tetratricopeptide repeat (CTPR) protein scaffold can be grafted with "KLVFF" derived peptides previously identified to inhibit protein aggregation and interact with amyloid fibrils, to produce proteins that bind along the surface of  $\alpha$ -synuclein fibrils with micromolar affinity. Given the ability to insert hydrophobic peptides to produce soluble, CTPR-based binders, this method may prove beneficial in screening for peptide modulators of protein aggregation.

**Keywords:**

Amyloid fibrils,  $\alpha$ -synuclein, protein scaffolds, fibril-binders

**Short statement:**

Consensus-designed tetratricopeptide repeat (CTPR) proteins can be endowed with additional functionality including specific client recruitment. Here we created stable, soluble CTPR-based binders that recognise  $\alpha$ -synuclein fibrils with micromolar affinity. The CTPR scaffold provides a facile way to test potential fibril-binding or aggregation-modulating peptides and to probe their mechanisms of action.

## Introduction:

Protein misfolding and aggregation into amyloid fibrils has been identified as a pathological hallmark for several neurodegenerative disorders, including Alzheimer's Disease (AD) and Parkinson's Disease (PD) (Chiti and Dobson 2017). In PD, the 14 kDa protein  $\alpha$ -synuclein aggregates to form cross- $\beta$  amyloid fibrils via a pathway that populates less organized oligomeric intermediates (Li et al. 2001; Serpell et al. 2000). Although it is believed that these oligomeric species are the key toxic species in the context of disease (Cremades et al. 2012; Fusco et al. 2017; Glabe 2006), the mature fibrils have a key role in propagating the aggregation process, for example, through secondary nucleation processes where protofibrils can accelerate amyloid formation through their fibril ends or fibril-surfaces (Buell et al. 2014; Cohen et al. 2013). Along with significant efforts to identify inhibitors of the aggregation process of  $\alpha$ -synuclein (Agerschou et al. 2019; Cheruvara et al. 2015; Chia et al. 2023; Meade et al. 2020; Santos et al. 2021), there has been great interest in identifying molecules that can bind specifically to the  $\alpha$ -synuclein fibrils, in order to modulate the aggregation process (Monsellier et al. 2020; Sangwan et al. 2020; Scheidt et al. 2021; Wallace et al. 2024). Furthermore, fibril-binding strategies are important for targeted protein degradation approaches to direct aggregates to the cell's natural proteostasis machinery for clearance (Lee et al. 2023; Tomoshige and Ishikawa 2021). Recent advances in *de novo* design have enabled the development of peptides and mini-proteins that bind to amyloid fibrils or with regions of monomeric amyloid-related proteins, creating high-affinity scaffolds that can modulate aggregation pathways (Agerschou et al. 2019; Sahtoe et al. 2024; Sangwan et al. 2020; Wallace et al. 2024). Moreover, rational antibody design strategies have made it possible to develop grafted amyloid-motif antibodies (gammabodies) that bind specifically to A $\beta$  fibrils with high affinity (Julian et al. 2019; Lee et al. 2016) and to create other conformational-specific antibodies that can recognise A $\beta$ <sub>1-42</sub> and  $\alpha$ -synuclein oligomers (Aprile et al. 2020; Kulenkampff et al. 2022). Interestingly, peptides derived from the KLVFF peptide (amino acids 16-20; A $\beta$ <sub>1-42</sub>) that is known to modulate A $\beta$  fibril formation (Tjernberg et al. 1996), have also been reported to bind to A $\beta$  fibrils and  $\alpha$ -synuclein fibrils (Aoraha et al. 2015; Wood et al. 2020). There are several studies that use the KLVFFAE peptide to bind to A $\beta$  fibrils, but the peptide itself is aggregation-prone and consequently often requires methods to increase its solubility and efficacy, including terminal-capping strategies (Aoraha et al. 2015), incorporating D-amino acids (Horsley et al. 2020), and coupling to gold and gadolinium nanoparticles (Gao et al. 2015; Plissonneau et al. 2016).

To test potential fibril-binding peptides and probe the mechanism by which they interact with amyloid fibrils, having an ultrastable scaffold for their display would be advantageous. The consensus-designed tetratricopeptide repeat protein (CTPR) scaffold comprises tandem arrays of a 34-residue  $\alpha$ -helix-turn- $\alpha$ -helix motif, and their simple, modular architecture and high stability makes them useful tools for protein engineering (Main et al. 2003; Perez-Riba and Itzhaki 2019). A rational design approach can be used to endow CTPR scaffolds with additional functionality including specific client recruitment via grafting of single and multiple copies of short linear binding motifs (SLiMs) between adjacent repeats in CTPR scaffolds (ranging from 2-6 repeat units), with diverse, precise, and predictable geometries for multivalent and

multi-functional display (Diamante et al. 2021; Madden et al. 2019; Ng 2024; Perez-Riba and Itzhaki 2019). Here we demonstrate that the KLVFFAE peptide and a variation, KLVFWAK (Wood et al. 2020), can be grafted onto our 3-repeat CTPR scaffold to produce soluble chimeras (FibSyn-CTPR and FibSyn2-CTPR) that can bind with micromolar affinity to  $\alpha$ -synuclein fibrils, along with a 4-repeat version containing two KLVFFAE motifs (between repeat 1-2 and between repeat 3-4; 2XFibSyn-CTPR4) that displays similar affinity for  $\alpha$ -synuclein fibrils with an increase in the number of associated molecules to the fibrils. Incubation of fluorophore-labelled fibril-binding CTPRs with unlabelled  $\alpha$ -synuclein fibrils resulted in full visualisation of the fibrillar structures by fluorescence microscopy, revealing that the interaction is with the entire surface of the fibrils and not isolated to specific regions. Finally, constraining these peptides in the inter-repeat loop of the CTPR-scaffold imparts a preference of the FibSyn-CTPR variants for  $\alpha$ -synuclein fibrils as compared to pre-formed A $\beta$ <sub>1-42</sub> fibrils.

## Results:

Single peptide motifs (KLVFFAE or KLVFWAK) were grafted between repeat 1-2 of a CTPR3 scaffold designed with DPRS inter-repeat loops and with a solvating helix (Main et al. 2003) to create FibSyn-CTPR3 and FibSyn2-CTPR3, respectively. A CTPR4 scaffold containing the KLVFFAE peptide between repeat 1-2 and between repeat 3-4 (2XFibSyn-CTPR4) was also designed (Figure 1). The CTPR4 design has DPNN inter-repeat loops and does not include a solvating helix, as Diamante and co-workers showed that the CTPR4 scaffold can accommodate 2-grafted binding loops without compromising the solubility or protein yield (Diamante et al. 2021). In all cases, DPNN linker regions flanked the fibril-binding peptides to increase the flexibility of the loops to maximise binding and to preserve the chemical environment of the residues adjacent to the loops (Madden et al. 2019).




**Figure 1: Schematic diagrams of CTPR scaffolds with incorporated fibril-binding motifs.** Alphafold2 models of A) the CTPR3 scaffold protein containing three-repeat units and a solvating helix (blue), B) FibSyn-CTPR3 containing three-repeat units, a solvating helix and a fibril-binding motif between repeat 1-2 (red), C) CTPR4 containing four-repeat units and D) 2XFibSyn-CTPR4 consisting of four-repeat units with a fibril-binding motif between repeat 1-2 and between repeat 3-4 (red). The peptide sequence for FibSyn is KLVFFAE and for FibSyn2 it is KLVFWAK. Full protein sequences are available in Table S1.

### Fibril-binding CTPRs retain scaffold structure and high stability:

All CTPR variants (and their respective negative controls wild-type (WT) CTPR3 and CTPR4, containing no additional inter-repeat loops) were expressed and purified, resulting in protein concentrations in the range of 120-320  $\mu\text{M}$ . We note that the 2XFibSyn CTPR4 has consistently lower concentrations after purification and evidence of aggregation has been observed above 100  $\mu\text{M}$  (upon thawing after storage). The insertion of the fibril-binding loops does not alter the native fold of the CTPR variants compared with their WT controls, as measured by circular dichroism (CD) spectroscopy (Figure 2, Fig. S1), and as expected, they decrease the native-state stability as determined by GdnHCl denaturation assays, but only by a modest amount (Table 1, Fig. S1, S2). In agreement with the chemical denaturation, thermal unfolding, assayed by measuring the CD spectrum at 90°C, shows that the helical content of the CTPR variants decreases more than those of the WT controls (Fig. S2) but the helicity is recovered when returning to 20°C (Figure 2).




**Figure 2: CD analysis of CTPR variant secondary structure.** Far-UV CD spectra of A) FibSyn-CTPR3, B) FibSyn2-CTPR3 and C) 2XFibSyn-CTPR4 at 20°C (black), 90°C (red) and returning to 20°C (blue). Protein concentration was 5  $\mu\text{M}$  in 50 mM sodium phosphate pH 7.5, 150 mM NaCl. Error bars are standard deviation calculated from three independent experiments.

**Table 1:** Parameters obtained from two-state fit of the GdnHCl-induced chemical denaturation experiments for CTPR variants.

| Protein | D <sub>50%</sub> (M) | <i>m</i> -value (kcal mol <sup>-1</sup> M <sup>-1</sup> ) |
|---------|----------------------|-----------------------------------------------------------|
| CTPR3   | 3.6 ± 0.1            | 2.6 ± 0.2                                                 |

|                |           |           |
|----------------|-----------|-----------|
| FibSyn-CTPR3   | 3.4 ± 0.1 | 2.1 ± 0.5 |
| FibSyn2-CTPR3  | 2.8 ± 0.2 | 1.3 ± 0.7 |
| CTPR4          | 4.8 ± 0.1 | 3.8 ± 0.6 |
| 2XFibSyn-CTPR4 | 3.8 ± 0.1 | 1.4 ± 0.5 |

### Fibril-binding CTPR variants interact with $\alpha$ -synuclein fibrils

To test whether the CTPR variants with inserted peptide motifs could recognize monomeric or fibrillar  $\alpha$ -synuclein, an initial dot blot assay was performed. After applying monomeric and fibrillar  $\alpha$ -synuclein to nitrocellulose membranes, fluorescently labelled CTPR variants were incubated to look for interactions. FibSyn-CTPR3, FibSyn2-CTPR3 and 2XFibSyn-CTPR4 showed positive interactions with  $\alpha$ -synuclein fibrils but not monomeric  $\alpha$ -synuclein (Fig. S3) and CTPR3-WT showed little interaction. To ensure that these specific interactions were not an artifact of immobilising the fibrils onto the nitrocellulose membrane, a fibril-pulldown assay was carried out. CTPR variants containing a single cysteine were labelled with Alexa Fluor™ 647 maleimide (Figure 3A) and incubated with  $\alpha$ -synuclein fibrils (Figure 3B). After extensive washing of the fibril/CTPR complexes to remove non-specific fluorescently labelled CTPRs, the fluorescence emission spectra were measured (Figure 3C, D) and corrected for labelling efficiency. Using these experiments, we could observe clear binding between the FibSyn-CTPR3, FibSyn2-CTPR3 and 2XFibSyn-CTPR4 variants and  $\alpha$ -synuclein fibrils. We observed lower fluorescence intensity for CTPR3-WT (Figure 3C) indicative of weaker binding, which we also noted in the dot-blot assay, whereas CTPR4-WT showed less fluorescence emission.




**Figure 3: Fibril pulldown assay to assess interactions between CTPR variants and  $\alpha$ -synuclein fibrils.** A) SDS-PAGE analysis of Alexa Fluor<sup>TM</sup> 647 labelled CTPR variants. B) TEM image of  $\alpha$ -synuclein fibrils prior to incubation with fluorescently labelled CTPRs. C) Fluorescence emission spectrum for CTPR3 (negative control), FibSyn-CTPR3 and FibSyn2-CTPR3 bound  $\alpha$ -synuclein fibrils. D) Fluorescence emission spectrum for CTPR4 (negative control) and 2XFibSyn-CTPR4 bound  $\alpha$ -synuclein fibrils. Error bars represent the standard deviation of two independent experiments.

### **Fibril-binding CTPR variants bind with micromolar affinity and along the entire fibril surface.**

To measure the binding affinities and stoichiometries of the interactions between the fibril-binding CTPRs and  $\alpha$ -synuclein fibrils, we applied a microfluidic diffusional sizing (MDS) approach. MDS allows us to determine the hydrodynamic radii ( $R_H$ ) of individual components in complex mixtures of species and to quantify their relative concentrations (Arosio et al. 2016; Scheidt et al. 2021; Scheidt et al. 2019). Using fluorescently labelled CTPR variants, we can monitor the change in  $R_H$  as they bind to large, pre-formed fibrils (PFFs) of  $\alpha$ -synuclein to quantify these interactions. MDS also provides insights into the stoichiometry of the CTPR variants in relation to the  $\alpha$ -synuclein units.

An initial comparison of the hydrodynamic radius of Alexa Fluor<sup>TM</sup> 647-labelled FibSyn-CTPR3 with increasing concentrations of unlabelled  $\alpha$ -synuclein PFFs shows a significant increase in  $R_H$ , whereas the same titration with Alexa Fluor<sup>TM</sup> 647-labelled CTPR3-WT shows no binding (Figure 4A). Next, we performed titrations for each fibril-binding CTPR variant and by analyzing the fraction of bound CTPR-variant at varying PFF concentrations, we determined the dissociation constants and stoichiometries (Table 2). All three fibril-binding variants had dissociation constants in the low micromolar range. When comparing the stoichiometry, i.e. the number of CTPR binders per  $\alpha$ -synuclein unit, the FibSyn-CTPR3 and FibSyn2-CTPR3 were very similar, 1 binder per 34 and 1 binder per 45, respectively, whereas for 2XFibSyn-CTPR4 the stoichiometry was approximately doubled with 1 binder per 14  $\alpha$ -synuclein units. This result suggests that, although the presence of two KLVFFAE peptide motifs does not increase the affinity of the CTPR variant for the fibrils, both binding motifs interact with the fibrils. In the 2XFibSyn CTPR4, the FibSyn motifs are offset by approximately 90° in the CTPR4 scaffold (Figure 1D) due to the CTPR proteins adopting a super-helical conformation, with eight repeats completing the superhelical turn (Kajander et al. 2007). This may compromise the individual binding affinity of each site, but as both interact with the fibrils the combined effect still results in micromolar affinity. Finally, to determine the localization of the fibril-binding CTPR variants on  $\alpha$ -synuclein fibrils, we imaged the Alexa Fluor<sup>TM</sup> 647-labelled CTPR variants bound to  $\alpha$ -synuclein fibrils using total internal reflection fluorescence (TIRF) microscopy (Figure 4E). In all cases, the CTPR variants are distributed throughout the fibril structures.

**Table 2: Binding of CTPR variants with  $\alpha$ -synuclein PFFs**

Values calculated from MDS experiments with the upper and lower boundaries of the 95% confident interval shown in square brackets.

| CTPR variant   | Dissociation constant $K_d$ ( $\mu\text{M}$ ) | Binding stoichiometry                           |
|----------------|-----------------------------------------------|-------------------------------------------------|
| FibSyn-CTPR3   | 3.23 [0.87, 6.90]                             | 1 binder per 34 [4, 66]<br>$\alpha$ -syn units  |
| FibSyn2-CTPR3  | 0.58 [0.02, 1.69]                             | 1 binder per 45 [27, 62]<br>$\alpha$ -syn units |
| 2XFibSyn-CTPR4 | 2.65 [1.47, 4.26]                             | 1 binder per 14 [2, 28]<br>$\alpha$ -syn units  |




**Figure 4: Microfluidic diffusional sizing (MDS) assay to determine binding affinity between fluorescently labelled CTPR variants and  $\alpha$ -synuclein preformed fibrils (PFFs).** A) Initial hydrodynamic radius measurements to compare CTPR3 (negative control) and FibSyn-CTPR3 interactions with increasing  $\alpha$ -synuclein PPF concentrations. The hydrodynamic radius for FibSyn-CTPR3 significantly

increases in the presence of  $\alpha$ -synuclein PFFs whereas no change is observed for CTPR3 (negative control). Fraction of FibSyn bound to  $\alpha$ -synuclein PFFs at varying concentrations of PFFs for B) FibSyn-CTPR3, C) FibSyn2-CTPR3 and D) 2XFibSyn-CTPR4. Each MDS assay was performed with different concentrations of CTPR variants including 75 nM (blue circles), 200 nM (red squares), 400 nM (black open diamonds) and 500 nM (black triangles). Dissociation constants are shown in Table 2. E) TIRF microscopy imaging of Alexa Fluor<sup>TM</sup> 647-labelled CTPR variants bound to  $\alpha$ -synuclein fibrils (prepared in a similar way to Figure 3 pulldown assay samples). Scale bars represent 5  $\mu$ m.

As the KLVFFAE peptide motif is well studied for its interactions with amyloid- $\beta$  ( $A\beta$ ) aggregates (Aoraha et al. 2015; Liu et al. 2023; Plissonneau et al. 2016; Wood et al. 2020), we tested if our fibril-binding CTPR variants showed specific interactions with pre-formed  $A\beta_{1-42}$  fibrils, using first a fibril pulldown assay for FibSyn2-CTPR3 versus CTPR3-WT and followed by MDS experiments for all three potential binders. In both experiments, we observe no interactions between the fibril-binding CTPR variants and  $A\beta_{1-42}$  fibrils (Fig. S4). It appears that constraining this peptide-motif within the inter-repeat loops of the CTPR scaffold imparts a conformational restraint that allows these variants to have a specificity for  $\alpha$ -synuclein fibrils over  $A\beta_{1-42}$  fibrils.

## Discussion:

Here we show the utility of the CTPR scaffold to not only display hydrophobic peptides in the inter-repeat loops to produce highly soluble protein, but to also produce CTPR-binders that have micromolar affinity for  $\alpha$ -synuclein fibrils. In addition, these CTPR-binders can be used to label the surfaces of *in vitro*  $\alpha$ -synuclein to enable visualization of the structures using fluorescence microscopy. It is interesting to note that constraining these peptides in the inter-repeat loops of the CTPRs introduces a selectivity for  $\alpha$ -synuclein fibrils over  $A\beta_{1-42}$  fibrils that has not been reported for the peptide motifs alone (Aoraha et al. 2015; Wood et al. 2020). Despite the similarities in the cross- $\beta$  structure of amyloid fibrils, the physicochemical attributes can differ significantly, and this may impact the fibril-binding properties of our CTPR-binders. For example, spectrally-resolved point accumulation for imaging in nanoscale topography (sPAINT) microscopy techniques have demonstrated that the surfaces of *in vitro*  $\alpha$ -synuclein fibrils are more hydrophobic than  $A\beta$  fibrils (Bongiovanni et al. 2016). However, further studies are needed to elucidate the binding epitopes on the  $\alpha$ -synuclein fibrils that are recognized by these CTPR-binders.

Although the interaction of the FibSyn-CTPRs with the surfaces of the synuclein fibrils may have implications for modulating aggregation kinetics (Buell et al. 2014), attempts to establish the effect on surface-catalyzed nucleation assays have been inconclusive, in large part due to the kinetic reaction conditions being carried out at a pH that is not ideal for the FibSyn-CTPRs, following close to the isoelectric points. Within the CTPR scaffold, only 8 residues are essential to ensure correct folding and, therefore, this system is amenable to protein engineering to improve its physicochemical properties (Main et al. 2003; Uribe et al. 2021); rational design approaches may lead to future variants that can be used to modulate aggregation kinetics.

Given the number of peptides reported in literature that alter  $\alpha$ -synuclein aggregation or bind to different  $\alpha$ -synuclein conformers (Cheruvara et al. 2015; Meade et al. 2020; Meade et al. 2021; Monsellier et al. 2020; Nahomi et al. 2015; Santos et al. 2021; Wood et al. 2020), our CTPR scaffold may provide a facile method to further study their mechanisms of action for modulating amyloid fibril formation and lead to the development of diagnostic tools and potential therapeutics.

## **Material and Methods:**

### **CTPR plasmid preparation and protein purification:**

CTPR constructs were cloned using gBlock oligos (Integrated DNA technologies) into a modified pRSET-B vector with FastDigest BamHI and HindIII restriction enzymes (ThermoFisher Scientific (UK) Ltd.) and Anza T4 DNA ligase master mix (Invitrogen, Paisley, UK). Plasmids were transformed into chemically competent C41 *E. coli* cells using standard heat-shock protocols. Colonies were grown at 37°C in 2xYT media (Formedium, Swaffham, UK) containing ampicillin (50  $\mu$ g/mL). Upon reaching OD<sub>600nm</sub> of 0.6-0.8, bacteria cultures were induced with isopropyl D-thiogalactopyranoside (IPTG, 0.5 mM, PanReac AppliChem, Darmstadt, Germany) and incubated (18 h, 20°C, 200 rpm). Cell pellets were collected by centrifugation from 125 mL of culture and resuspended in 15 mL lysis buffer (50 mM sodium phosphate (pH 8.0), 150 mM NaCl, 1 mg/mL DNase I, 1 cOmplete EDTA-free protease inhibitor tablet (Roche Diagnostics GmbH) for each 50 mL of lysis buffer). Cells were lysed using an EmulsiFlex C5 homogeniser (Avestin, Mannheim, Germany) (3-4X, 10000-15000 psi) and centrifuged. The supernatants were purified using HisTrap HP columns (1 mL, Cytiva Ltd., Little Chalfont, UK) on an AKTA PURE protein purification system (Cytiva Ltd.) with Buffer A (50 sodium phosphate (pH 8.0), 150 mM NaCl, and a linear gradient (0-80% Buffer A + 0.5 M imidazole, 15 column volumes (CV)). Purification buffers for the Cys-variants contained 0.5 mM TCEP. Protein purity was confirmed using SDS-PAGE and electrospray ionisation mass spectrometry performed on a Xevo G2 mass spectrometer with data analyzed using MassLynx software (Waters UK) (Yusuf Hamied Department of Chemistry, University of Cambridge, UK). The amino acid sequences and masses of the proteins are listed in (Table S1).

### **Alexa Fluor™ 647-maleimide labelling of Cys-CTPR variants:**

Cys-variants of the CTPR proteins (100  $\mu$ M, 50 mM sodium phosphate buffer, 150 mM NaCl, pH 8, 0.5 mM TCEP) were labelled by reacting with a 2.5X molar excess of Alexa Fluor™ 647 C<sub>2</sub> maleimide or Alexa Fluor™ 594 C<sub>2</sub> maleimide (Invitrogen) and incubated (2 hr, room temperature (RT)). 1 mM DTT was added, and excess dye was removed using Pierce dye removal columns as described in the manufacturer's protocol (ThermoFisher). UV-vis spectra for the fluorophore-labelled protein were collected on a Nanodrop 2000 spectrophotometer (ThermoFisher) and the protein concentration and labelling efficiency were calculated using Equations 1 and 2 (Alexa Fluor™ 594) and Equations 3 and 4 (Alexa Fluor™ 647):

$$\text{Eq. 1: Protein Concentration (M)} = (A_{280} - (A_{590} \times 0.56)) / [\epsilon_{280} \text{ of protein}]$$

Eq. 2: Labelling Efficiency (%) =  $(100 \times A_{590}) / (73,000 \times \text{Protein Concentration (M)})$

Eq. 3: Protein Concentration (M) =  $(A_{280} - (A_{650} \times 0.03)) / [\epsilon_{280} \text{ of protein}]$

Eq. 4: Labelling Efficiency (%) =  $(100 \times A_{650}) / (239,000 \times \text{Protein Concentration (M)})$

### **Circular Dichroism (CD) spectroscopy**

CD measurements were conducted with a Chirascan CD spectrometer (Applied Photophysics, Leatherhead, UK) in 1 mm pathlength Precision Cells (110-QS; Hellma Analytics, Müllheim, Germany). Protein samples at 5  $\mu\text{M}$  in sodium phosphate buffer were measured across 205-250 nm wavelengths. Spectra, taken at 1 nm intervals every 0.5 s, were recorded at 20°C, then 90°C, and again at 20°C. Each protein measurement was independently repeated three times, with data baseline corrected for buffer and averaged.

### **Guanidine Hydrochloride (GdnHCl) denaturation assay**

The different GdnHCl concentrations were prepared by mixing the appropriate volumes of 50 mM sodium phosphate buffer pH 7.5, 150 mM NaCl, 7 M GdnHCl and 50 mM sodium phosphate buffer using a Microlab ML510B (Hamilton, Bonaduz, Switzerland). The protein concentration used was 15  $\mu\text{M}$  and protein and solutions were dispensed into 96-well, half-area, black polystyrene plates (Corning) and covered with 96-well microplate aluminium sealing tape (Corning). Samples were equilibrated at 25 °C for 2 hr. Emission at 360 nm was measured using a CLARIOstar® Microplate Reader (BMG Labtech, Aylesbury, UK). The top optic was used in precise mode for 2 cycles with an excitation wavelength of 295 nm and a dichroic PL325 nm filter at 25°C. Each measurement was performed in triplicate and three independent experiments were carried out for each protein variant unless otherwise specified. The data were fit to a two-state model, with denaturation curves fitted directly in GraphPad Prism 10 as described by Perez-Riba et al. (Perez-Riba and Itzhaki 2017).

### **$\alpha$ -Synuclein fibril preparation**

A T7-7 plasmid encoding  $\alpha$ -synuclein (Hoyer et al. 2002) was transformed and expressed in BL21(DE3) E. coli (NEB (UK) Ltd.), and purification was carried out as detailed in Bell et al. (Bell et al. 2023).  $\alpha$ -Synuclein fibrils were generated by incubating 100  $\mu\text{M}$   $\alpha$ -synuclein (PBS with 0.01% azide) for 72-96 hr (37°C, 200 rpm). After incubation, fibril samples were mixed with Thioflavin-T (ThT) (250  $\mu\text{M}$ ) and ThT fluorescence was measured to using a CLARIOstar® Microplate Reader (BMG Labtech) with excitation at 440 nm and emission spectra collected between 465-580 nm. The fibrils were centrifuged (10 min, 15,000g) and the supernatant was removed. The fibril pellets were washed with PBS (2X) followed by centrifugation. The washed fibrils were resuspended in PBS and sonicated (low power, 50% pulse, 15 sec) with a Sonopuls probe sonicator (Bandelin, HD 2070) to produce preformed fibrils (PFFs). These PFFs were used to seed fresh  $\alpha$ -synuclein fibrils by adding 10% v/v to monomeric protein and incubating for 24-48 hr (37°C, quiescent). All fibril samples were imaged by Transmission electron microscopy (TEM) prior to using. For TEM analysis, fibrils were diluted to 5-10  $\mu\text{M}$  and incubated (3 min) on carbon-coated copper grids (EM Resolutions, Keele, UK), followed by washing with deionised water

and staining with UranylLess (Labtech, Rotheram UK) for 2 min (2X) then washed quickly with water. TEM images were taken on a Tecnai G2 80-200 kV transmission electron microscope (Cambridge Advanced Imaging Centre (CAIC), University of Cambridge). Images were analysed using the SIS Megaview II Image Capture system.

#### **Dot blot assay:**

Onto nitrocellulose membranes, 5  $\mu$ L drops of PBS only,  $\alpha$ -synuclein monomer (10  $\mu$ M) and  $\alpha$ -synuclein fibrils (10  $\mu$ M) were applied and dried. This was repeated four times. The membrane was incubated in 2% w/v bovine serum albumin (BSA) in TBS-T (Tris buffered saline with 0.1% v/v Tween 20) (4°C, overnight, roller). The membrane was incubated with a fluorophore-labelled CTPR variant solution (1  $\mu$ M, 50 mM phosphate pH 8, 150 mM NaCl) (1 hr, RT, roller). The membrane was washed by incubating in TBS-T (3X, 10 min) and then imaged with a LiCor Odyssey (Li-Cor, Lincoln, USA) at 600 nm with a 2 min exposure (Alexa Fluor™ 594) or 700 nm with a 2 min exposure (Alexa Fluor™ 647) and analysed with Empiria Studio™ software (Li-Cor).

#### **Fibril pulldown assay:**

Aliquots of  $\alpha$ -synuclein fibrils (35  $\mu$ L of 70  $\mu$ M solutions (based on monomer concentration)) were incubated with Alexa Fluor™ 647-labelled CTPR variants (35  $\mu$ L of 20  $\mu$ M solutions) and incubated (30 min, RT). The samples were centrifuged (10 min, 15000g, RT) and the supernatant was removed. The fibril pellets were washed twice with PBS-T (phosphate buffered saline with 0.1% v/v Tween20). The pellets were resuspended in 35  $\mu$ L PBS and the fluorescence signal (bound to the fibrils) was measured in a 384-well black microtitre plate (Corning) with a CLARIOstar® Microplate Reader (BMG Labtech, Aylesbury, UK) with an excitation wavelength of 622 nm and collecting the emission spectrum between 650-710 nm. The spectra were corrected for the labelling efficiency of each CTPR-variant and normalised to the 2XFibSyn-CTPR4 readings. Data from two independent experiments were averaged.

#### **Microfluidic Diffusional Sizing (MDS) experiments:**

Fabrication and operation of the microfluidic chips for MDS experiments have been shown previously (Arosio et al. 2016; McDonald and Whitesides 2002; Qin et al. 2010). In brief, microfluidic devices were obtained by standard soft-lithography in polydimethylsiloxane (PDMS, Momentive RTV615, Techsil, Bidford on Avon, UK). Carbon nanoparticles (ca. 13 nm, Plasmachem, Berlin, Germany) were mixed into the PDMS before curing to avoid channel cross-talk, as previously reported (Herling et al. 2016). After curing, the PDMS slips were bonded onto microscopy slides (Epredia Cut Microscope Slide, ThermoFisher) by application of an oxygen plasma. Sample and co-flow buffer were loaded onto the chip from reservoirs at the respective inlets by applying a negative pressure at the outlet by means of a glass syringe (Hamilton) connected to a syringe pump (neMESYS, Cetoni GmbH, Korbussen, Germany) with a typical flow rate of 100  $\mu$ L/min. A custom-built, inverted epifluorescence microscope was used for the detection of the microfluidic profiles. For excitation, light from a brightfield LED light source (Thorlabs, Newton, NJ, USA) was directed through the Cy5-4040C-000 Filter set from Semrock (Laser 2000, Huntingdon, UK) and detected with charge-coupled-device camera (Prime 95B, Photometrics, Tucson, AZ, USA). Images were taken using Micro Manager (Version

I.4.23 20170327). Synuclein fibril concentrations are determined by incubation of the fibrils with 4 M GdnHCl and subsequent UV absorption spectroscopy ( $\epsilon_{275\text{ nm}} = 5600\text{ cm}^{-1}\text{ M}^{-1}$ ), and are reported with respect to monomer equivalents. Affinities were determined by determining the hydrodynamic radius of protein complex between the CTPR variant with  $\alpha$ S fibrils at different concentrations of both Alexa-647 labelled CTPR variant and unlabelled  $\alpha$ S PFFs. With fitting this data with respect to two species, i.e. bound and unbound CTPR variant, it becomes possible to determine the size of the complex along with the fraction of bound CTPR variant. The fraction of bound CTPR variant can be determined with respect to Equation 5 (Scheidt et al. 2021; Scheidt et al. 2019).

Equation 5:

$$\frac{[\alpha SF]}{[F]_0} = \left( \frac{[F]_0 + [\alpha S]_0 + K_d}{2} \pm \sqrt{\left( \frac{[F]_0 + [\alpha S]_0 + K_d}{2} \right)^2 - [\alpha S]_0 [F]_0} \right) \frac{1}{[F]_0}$$

### Fluorescence Microscopy:

$\mu$ -slide 8 well high glass bottom plates (Ibidi) were treated by cleaning with 1M KOH (30-45 min) and rinsed with PBS (2X). To the well, a poly-L-lysine solution (0.1%) was added and incubated (45 min) followed by washing with PBS (2X). The fibrils bound to Alexa-647 labelled CTPR proteins (10-15  $\mu$ M) were prepared as described above and these were incubated in a well (30 min), followed by removal of the solution and washing with PBS (1X). Imaging was done on an inverted Olympus IX-73 microscope (Olympus Corporation, Japan), using a TIRF oil-immersion objective (Apochromat 100 $\times$ , NA 1.49 Oil, Olympus) with an exposur time of 0.01 sec, 100 frames. After being filtered through a dichroic filter cube (Cairn OptoSpin) and a wavelength-specific emission filter (Semrock), images were captured with an electron-multiplying charge-coupled device (EMCCD) camera (Andor iXon3 897) and processed using ImageJ.

### Supplementary Information:

The file “Bismut Schneider et al SI 2025.pdf”, contains a table of the amino acid sequences for all designed protein scaffolds, characterization of control protein scaffolds and additional experiments to support the main manuscript.

### Acknowledgements:

The authors would like to thank the staff at Cambridge Advanced Imaging Centre (CAIC), University of Cambridge, UK for their assistance with transmission electron microscopy imaging. M.M.S. was funded from the Frances and Augustus Newman Foundation. This work was supported by an MRC Career Development Award (MR/W01632X/1, J.R.K.) and the Royal Society (RGS\R1\231207, J.R.K.). J.R.K. and L.S.I acknowledge funding from the Rosetrees Trust (CF2\100013). G.S.K.S acknowledges funding from the Wellcome Trust (065807/Z/01/Z, 203249/Z/16/Z), the UK Medical Research Council (MR/K02292X/1), Alzheimer’s Research UK (ARUK-PG013-14), the Michael J Fox Foundation (16238, 022159), and Infinitus (China) Company Ltd. T.P.J.K. acknowledges the European Research Council under the

European Union's Horizon 2020 research and innovation program through the ERC grant DiProPhys (agreement ID 101001615).

### **Author Contributions:**

L.S.I. and J.R.K designed the conceptual framework of the study. S.B., M.M.S., M.M., Y.F., E.J.W., M.D.G. and J.R.K. performed the experiments. S.B., M.M.S., M.M., Y.F., E.J.W., M.D.G. T.P.J.K., G.S.K.S, L.S.I and J.R.K. contributed to data acquisition and interpretation. J.R.K wrote the manuscript with contributions from all authors.

### **References:**

- Agerschou ED, Flagmeier P, Saridaki T, Galvagnion C, Komnig D, Heid L, Prasad V, Shaykhalishahi H, Willbold D, Dobson CM et al. 2019. An engineered monomer binding-protein for alpha-synuclein efficiently inhibits the proliferation of amyloid fibrils. *Elife*. 8:e46112.
- Aoraha E, Candreva J, Kim JR. 2015. Engineering of a peptide probe for beta-amyloid aggregates. *Mol Biosyst*. 11(8):2281-2289.
- Aprile FA, Sormanni P, Podpolny M, Chhangur S, Needham LM, Ruggeri FS, Perni M, Limbocker R, Heller GT, Sneideris T et al. 2020. Rational design of a conformation-specific antibody for the quantification of abeta oligomers. *Proc Natl Acad Sci U S A*. 117(24):13509-13518.
- Arosio P, Muller T, Rajah L, Yates EV, Aprile FA, Zhang Y, Cohen SI, White DA, Herling TW, De Genst EJ et al. 2016. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. *ACS Nano*. 10(1):333-341.
- Bell R, Vendruscolo M, Kumita JR. 2023. Probing the effects of n-terminal acetylation on alpha-synuclein structure, aggregation and cytotoxicity. *Methods Enzymol*. 686:45-65.
- Bongiovanni MN, Godet J, Horrocks MH, Tosatto L, Carr AR, Wirthensohn DC, Ranasinghe RT, Lee JE, Ponjavic A, Fritz JV et al. 2016. Multi-dimensional super-resolution imaging enables surface hydrophobicity mapping. *Nat Commun*. 7:13544.
- Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, Linse S, Dobson CM. 2014. Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation. *Proc Natl Acad Sci U S A*. 111(21):7671-7676.
- Cheruvara H, Allen-Baume VL, Kad NM, Mason JM. 2015. Intracellular screening of a peptide library to derive a potent peptide inhibitor of alpha-synuclein aggregation. *J Biol Chem*. 290(12):7426-7435.
- Chia S, Faidon Brotzakis Z, Horne RI, Possenti A, Mannini B, Cataldi R, Nowinska M, Staats R, Linse S, Knowles TPJ et al. 2023. Structure-based discovery of small-molecule inhibitors of the autocatalytic proliferation of alpha-synuclein aggregates. *Mol Pharm*. 20(1):183-193.
- Chiti F, Dobson CM. 2017. Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. *Annu Rev Biochem*. 86:27-68.
- Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP. 2013. Proliferation of amyloid-

- beta42 aggregates occurs through a secondary nucleation mechanism. *Proc Natl Acad Sci U S A.* 110(24):9758-9763.
- Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA et al. 2012. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. *Cell.* 149(5):1048-1059.
- Diamante A, Chaturbedy PK, Rowling PJE, Kumita JR, Eapen RS, McLaughlin SH, de la Roche M, Perez-Riba A, Itzhaki LS. 2021. Engineering mono- and multi-valent inhibitors on a modular scaffold. *Chem Sci.* 12(3):880-895.
- Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N et al. 2017. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. *Science.* 358(6369):1440-1443.
- Gao N, Sun H, Dong K, Ren J, Qu X. 2015. Gold-nanoparticle-based multifunctional amyloid-beta inhibitor against alzheimer's disease. *Chemistry.* 21(2):829-835.
- Glabe CG. 2006. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. *Neurobiol Aging.* 27(4):570-575.
- Herling TW, O'Connell DJ, Bauer MC, Persson J, Weininger U, Knowles TP, Linse S. 2016. A microfluidic platform for real-time detection and quantification of protein-ligand interactions. *Biophys J.* 110(9):1957-1966.
- Horsley JR, Jovceviski B, Wegener KL, Yu J, Pukala TL, Abell AD. 2020. Rationally designed peptide-based inhibitor of abeta42 fibril formation and toxicity: A potential therapeutic strategy for alzheimer's disease. *Biochem J.* 477(11):2039-2054.
- Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. 2002. Dependence of alpha-synuclein aggregate morphology on solution conditions. *J Mol Biol.* 322(2):383-393.
- Julian MC, Rabia LA, Desai AA, Arsiwala A, Gerson JE, Paulson HL, Kane RS, Tessier PM. 2019. Nature-inspired design and evolution of anti-amyloid antibodies. *J Biol Chem.* 294(21):8438-8451.
- Kajander T, Cortajarena AL, Mochrie S, Regan L. 2007. Structure and stability of designed tpr protein superhelices: Unusual crystal packing and implications for natural tpr proteins. *Acta Crystallogr D Biol Crystallogr.* 63(Pt 7):800-811.
- Kulenkampff K, Emin D, Staats R, Zhang YP, Sakhnini L, Kouli A, Rimón O, Lobanova E, Williams-Gray CH, Aprile FA et al. 2022. An antibody scanning method for the detection of alpha-synuclein oligomers in the serum of parkinson's disease patients. *Chem Sci.* 13(46):13815-13828.
- Lee CC, Julian MC, Tiller KE, Meng F, DuConge SE, Akter R, Raleigh DP, Tessier PM. 2016. Design and optimization of anti-amyloid domain antibodies specific for beta-amyloid and islet amyloid polypeptide. *J Biol Chem.* 291(6):2858-2873.
- Lee J, Sung KW, Bae EJ, Yoon D, Kim D, Lee JS, Park DH, Park DY, Mun SR, Kwon SC et al. 2023. Targeted degradation of  $\alpha$ -synuclein aggregates in parkinson's disease using the autotac technology. *Mol Neurodegener.* 18(1):41.
- Li J, Uversky VN, Fink AL. 2001. Effect of familial parkinson's disease point mutations a30p and a53t on the structural properties, aggregation, and fibrillation of human alpha-synuclein. *Biochemistry.* 40(38):11604-11613.
- Liu Z, Deng Q, Qin G, Yang J, Zhang H, Ren J, Qu X. 2023. Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils. *Chem* 9(7):2016-2038.

- Madden SK, Perez-Riba A, Itzhaki LS. 2019. Exploring new strategies for grafting binding peptides onto protein loops using a consensus-designed tetratricopeptide repeat scaffold. *Protein Sci.* 28(4):738-745.
- Main ER, Xiong Y, Cocco MJ, D'Andrea L, Regan L. 2003. Design of stable alpha-helical arrays from an idealized tpr motif. *Structure.* 11(5):497-508.
- McDonald JC, Whitesides GM. 2002. Poly(dimethylsiloxane) as a material for fabricating microfluidic devices. *Acc Chem Res.* 35(7):491-499.
- Meade RM, Morris KJ, Watt KJC, Williams RJ, Mason JM. 2020. The library derived 4554w peptide inhibits primary nucleation of alpha-synuclein. *J Mol Biol.* 432(24):166706.
- Meade RM, Watt KJC, Williams RJ, Mason JM. 2021. A downsized and optimised intracellular library-derived peptide prevents alpha-synuclein primary nucleation and toxicity without impacting upon lipid binding. *J Mol Biol.* 433(24):167323.
- Monsellier E, Bendifallah M, Redeker V, Melki R. 2020. Polypeptides derived from alpha-synuclein binding partners to prevent alpha-synuclein fibrils interaction with and take-up by cells. *PLoS One.* 15(8):e0237328.
- Nahomi RB, DiMauro MA, Wang B, Nagaraj RH. 2015. Identification of peptides in human hsp20 and hsp27 that possess molecular chaperone and anti-apoptotic activities. *Biochem J.* 465(1):115-125.
- Ng TLCH, M.P.; Maristany, M.J.; Wilde, E.J.; Sneideris, T.; Huertas, J.; Agbetiamah, B.K.; Furukawa, M.; Joseph, J.A.; Knowles, T.P.J.; Collepardo-Guevara, R.; Itzhaki, L.S.; Kumita, J.R. 2024. Tandem-repeat proteins introduce tuneable properties to engineered biomolecular condensates. *bioRxiv*.
- Perez-Riba A, Itzhaki LS. 2017. A method for rapid high-throughput biophysical analysis of proteins. *Sci Rep.* 7(1):9071.
- Perez-Riba A, Itzhaki LS. 2019. The tetratricopeptide-repeat motif is a versatile platform that enables diverse modes of molecular recognition. *Curr Opin Struct Biol.* 54:43-49.
- Plissonneau M, Pansieri J, Heinrich-Balard L, Morfin JF, Stransky-Heilkron N, Rivory P, Mowat P, Dumoulin M, Cohen R, Allemann E et al. 2016. Gd-nanoparticles functionalization with specific peptides for ss-amyloid plaques targeting. *J Nanobiotechnology.* 14(1):60.
- Qin D, Xia Y, Whitesides GM. 2010. Soft lithography for micro- and nanoscale patterning. *Nat Protoc.* 5(3):491-502.
- Sahtoe DD, Andrzejewska EA, Han HL, Rennella E, Schneider MM, Meisl G, Ahlrichs M, Decarreau J, Nguyen H, Kang A et al. 2024. Design of amyloidogenic peptide traps. *Nat Chem Biol.* 20(8):981-990.
- Sangwan S, Sahay S, Murray KA, Morgan S, Guenther EL, Jiang L, Williams CK, Vinters HV, Goedert M, Eisenberg DS. 2020. Inhibition of synucleinopathic seeding by rationally designed inhibitors. *Elife.* 9.
- Santos J, Gracia P, Navarro S, Pena-Diaz S, Pujols J, Cremades N, Pallares I, Ventura S. 2021. Alpha-helical peptidic scaffolds to target alpha-synuclein toxic species with nanomolar affinity. *Nat Commun.* 12(1):3752.
- Scheidt T, Carozza JA, Kolbe CC, Aprile FA, Tkachenko O, Bellaiche MMJ, Meisl G, Peter QAE, Herling TW, Ness S et al. 2021. The binding of the small heat-shock protein alphas-crystallin to fibrils of alpha-synuclein is driven by entropic forces. *Proc Natl Acad Sci U S A.* 118(38).
- Scheidt T, Lapinska U, Kumita JR, Whiten DR, Klenerman D, Wilson MR, Cohen SIA, Linse S, Vendruscolo M, Dobson CM et al. 2019. Secondary nucleation and

- elongation occur at different sites on alzheimer's amyloid-beta aggregates. *Sci Adv.* 5(4):eaau3112.
- Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. 2000. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. *Proc Natl Acad Sci U S A.* 97(9):4897-4902.
- Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. 1996. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. *J Biol Chem.* 271(15):8545-8548.
- Tomoshige S, Ishikawa M. 2021. Protacs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders. *Angew Chem Int Ed Engl.* 60(7):3346-3354.
- Uribe KB, Guisasola E, Aires A, Lopez-Martinez E, Guedes G, Sasselli IR, Cortajarena AL. 2021. Engineered repeat protein hybrids: The new horizon for biologic medicines and diagnostic tools. *Acc Chem Res.* 54(22):4166-4177.
- Wallace HM, Yang H, Tan S, Pan HS, Yang R, Xu J, Jo H, Condello C, Polizzi NF, DeGrado WF. 2024. De novo design of peptides that bind specific conformers of alpha-synuclein. *Chem Sci.* 15(22):8414-8421.
- Wood A, Chau E, Yang Y, Kim JR. 2020. A klvffae-derived peptide probe for detection of alpha-synuclein fibrils. *Appl Biochem Biotechnol.* 190(4):1411-1424.